BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58. [PMID: 12969081 DOI: 10.1046/j.1365-2036.2003.01681.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 65] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chung H, Green PHR, Wang TC, Kong XF. Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence. J Inflamm Res 2021;14:5187-200. [PMID: 34675597 DOI: 10.2147/JIR.S280953] [Reference Citation Analysis]
3 Li Y, Sun F, Yue TT, Wang FX, Yang CL, Luo JH, Rong SJ, Xiong F, Zhang S, Wang CY. Revisiting the Antigen-Presenting Function of β Cells in T1D Pathogenesis. Front Immunol 2021;12:690783. [PMID: 34335595 DOI: 10.3389/fimmu.2021.690783] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
4 Fox LE, Locke MC, Lenschow DJ. Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease. Front Immunol 2020;11:606874. [PMID: 33408718 DOI: 10.3389/fimmu.2020.606874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
5 Stefan-Lifshitz M, Karakose E, Cui L, Ettela A, Yi Z, Zhang W, Tomer Y. Epigenetic modulation of β cells by interferon-α via PNPT1/mir-26a/TET2 triggers autoimmune diabetes. JCI Insight 2019;4:126663. [PMID: 30721151 DOI: 10.1172/jci.insight.126663] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
6 Qaisar N, Jurczyk A, Wang JP. Potential role of type I interferon in the pathogenic process leading to type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2018;25:94-100. [PMID: 29369915 DOI: 10.1097/MED.0000000000000399] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
7 Iliescu L, Mercan-Stanciu A, Toma L, Ioanitescu ES. A SEVERE CASE OF HYPERGLYCEMIA IN A KIDNEY TRANSPLANT RECIPIENT UNDERGOING INTERFERON-FREE THERAPY FOR CHRONIC HEPATITIS C. Acta Endocrinol (Buchar) 2018;14:533-8. [PMID: 31149309 DOI: 10.4183/aeb.2018.533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Sossau D, Kofler L, Eigentler T. Type 1 diabetes mellitus caused by treatment with low-dose interferon-α in a melanoma patient. Melanoma Research 2017;27:516-8. [DOI: 10.1097/cmr.0000000000000381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
9 Newby BN, Mathews CE. Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front Endocrinol (Lausanne) 2017;8:232. [PMID: 28959234 DOI: 10.3389/fendo.2017.00232] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
10 Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther. 2017;15:737-746. [PMID: 28696154 DOI: 10.1080/14787210.2017.1354697] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
11 Marro BS, Ware BC, Zak J, de la Torre JC, Rosen H, Oldstone MB. Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-α signaling. Proc Natl Acad Sci U S A 2017;114:3708-13. [PMID: 28325871 DOI: 10.1073/pnas.1700878114] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
12 Khan WA. Recombinant Interferon Alpha-2b is a High-Affinity Antigen for Type 1 Diabetes Autoantibodies. Can J Diabetes 2017;41:217-23. [PMID: 28024793 DOI: 10.1016/j.jcjd.2016.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015;38:1153-1168. [PMID: 26370106 DOI: 10.1007/s40264-015-0339-z] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
14 Yu Q, Zhao B, Gui J, Katlinski KV, Brice A, Gao Y, Li C, Kushner JA, Koumenis C, Diehl JA, Fuchs SY. Type I interferons mediate pancreatic toxicities of PERK inhibition. Proc Natl Acad Sci U S A 2015;112:15420-5. [PMID: 26627716 DOI: 10.1073/pnas.1516362112] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
15 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
16 Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. J Interferon Cytokine Res. 2015;35:981-989. [PMID: 26308911 DOI: 10.1089/jir.2014.0200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
17 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
18 Ruhl CE, Menke A, Cowie CC, Everhart JE. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology 2014;60:1139-49. [PMID: 24500979 DOI: 10.1002/hep.27047] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 7.9] [Reference Citation Analysis]
19 Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2011;2:113-28. [PMID: 25083207 DOI: 10.1177/2042098611406318] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
20 Lee CN, Lew AM, Wu L. The potential role of dendritic cells in the therapy of Type 1 diabetes. Immunotherapy 2013;5:591-606. [PMID: 23725283 DOI: 10.2217/imt.13.48] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
21 Matsuoka K, Saito M, Shibata K, Sekine M, Shitara H, Taya C, Zhang X, Takahashi TA, Kohno K, Kikkawa Y, Yonekawa H. Generation of mouse models for type 1 diabetes by selective depletion of pancreatic beta cells using toxin receptor-mediated cell knockout. Biochem Biophys Res Commun 2013;436:400-5. [PMID: 23747725 DOI: 10.1016/j.bbrc.2013.05.114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
22 Ibrahim HM, El-Elaimy IA, Saad Eldien HM, Badr BM, Rabah DM, Badr G. Blocking type I interferon signaling rescues lymphocytes from oxidative stress, exhaustion, and apoptosis in a streptozotocin-induced mouse model of type I diabetes. Oxid Med Cell Longev 2013;2013:148725. [PMID: 23533683 DOI: 10.1155/2013/148725] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
23 Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, Lehuen A. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med. 2013;19:65-73. [PMID: 23242473 DOI: 10.1038/nm.3042] [Cited by in Crossref: 278] [Cited by in F6Publishing: 288] [Article Influence: 27.8] [Reference Citation Analysis]
24 Grassia G, MacRitchie N, Platt AM, Brewer JM, Garside P, Maffia P. Plasmacytoid dendritic cells: biomarkers or potential therapeutic targets in atherosclerosis? Pharmacol Ther 2013;137:172-82. [PMID: 23059425 DOI: 10.1016/j.pharmthera.2012.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
25 Oka R, Hiroi N, Shigemitsu R, Sue M, Oshima Y, Yoshida-Hiroi M. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review. Clin Med Insights Endocrinol Diabetes. 2011;4:39-45. [PMID: 22879793 DOI: 10.4137/cmed.s7815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
26 Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, Maruyama T, Hanafusa T; Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 2011;34:2084-9. [PMID: 21775762 DOI: 10.2337/dc10-2274] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
27 Nakanishi K, Saitoh S. Clinical and genetic characteristics of patients with type 1 diabetes associated with interferon therapy. Diabetes Care 2011;34:471-3. [PMID: 21270202 DOI: 10.2337/dc10-1237] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
28 Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-223. [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 9.0] [Reference Citation Analysis]
29 Muraishi K, Sasaki Y, Kato T, Inada C, Tajiri Y, Yamada K. Classification and characteristics of interferon-related diabetes mellitus in Japan: Interferon and diabetes mellitus. Hepatology Research 2011;41:184-8. [DOI: 10.1111/j.1872-034x.2010.00753.x] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
30 Lee YN, Jeong SW, Lim JH, Ryu YS, Jeon SR, Kim SK, Jang JY, Kim YS, Kim BS, Roh MO. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C]. Korean J Hepatol. 2010;16:187-191. [PMID: 20606504 DOI: 10.3350/kjhep.2010.16.2.187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Tovey MG, Lallemand C. Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel) 2010;3:1162-86. [PMID: 27713294 DOI: 10.3390/ph3041162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
32 Biggioggero M, Gabbriellini L, Meroni PL. Type I interferon therapy and its role in autoimmunity. Autoimmunity 2010;43:248-54. [DOI: 10.3109/08916930903510971] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
33 Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves’ disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract. 2009;86:e19-e21. [PMID: 19744739 DOI: 10.1016/j.diabres.2009.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
34 Burdick LM, Somani N, Somani AK. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 2009;8:459-72. [PMID: 19548860 DOI: 10.1517/14740330903066726] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
35 Daniel AL, Houlihan JL, Blum JS, Walsh JP. Type B insulin resistance developing during interferon-alpha therapy. Endocr Pract 2009;15:153-7. [PMID: 19289328 DOI: 10.4158/EP.15.2.153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Lo Y, Chang S, Sheng W, Hung C, Chang S. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature: . European Journal of Gastroenterology & Hepatology 2009;21:478-81. [DOI: 10.1097/meg.0b013e328317f4c8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
37 Soetekouw PM, Koopman M, Burger D, Tjan-Heijnen VC, De Mulder PH. Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma. Acta Oncol 2009;48:154-6. [PMID: 19101828 DOI: 10.1080/02841860802047403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
38 Hashemi N, Rossi S, Navarro VJ, Herrine SK. Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2008;7:771-781. [PMID: 18983223 DOI: 10.1517/14740330802423291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
39 Marx J, Schwenger V, Blank N, Stremmel W, Encke J. [Hemoptysis and acute renal failure in a 29-year-old patient with chronic hepatitis C infection]. Internist (Berl) 2008;49:1120-5. [PMID: 18604512 DOI: 10.1007/s00108-008-2099-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
40 Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 2009;58:138-45. [PMID: 18835928 DOI: 10.2337/db08-0964] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 5.6] [Reference Citation Analysis]
41 Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008;105:12439-44. [PMID: 18716002 DOI: 10.1073/pnas.0806439105] [Cited by in Crossref: 130] [Cited by in F6Publishing: 129] [Article Influence: 9.3] [Reference Citation Analysis]
42 Lv YY, Shi BY, Guo H. Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B. World J Gastroenterol 2008; 14(29): 4713-4715 [PMID: 18698691 DOI: 10.3748/wjg.14.4713] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
43 Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH, Hoekstra JB, Jansen PL. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int. 2008;28:39-46. [PMID: 18031478 DOI: 10.1111/j.1478-3231.2007.01610.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
44 Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. J Cancer Surviv 2007;1:261-74. [PMID: 18648961 DOI: 10.1007/s11764-007-0038-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
45 Tosone G, Borgia G, Gentile I, Cerini R, Conte MC, Orlando R, Piazza M. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol 2007;44:167-9. [PMID: 17721757 DOI: 10.1007/s00592-007-0259-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
46 Lonardo A, Carulli N, Loria P. HCV and diabetes. A two-question-based reappraisal. Dig Liver Dis. 2007;39:753-761. [PMID: 17611176 DOI: 10.1016/j.dld.2007.05.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
47 Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol. 2007;19:61-66. [PMID: 17143098 DOI: 10.1097/bor.0b013e328010c547] [Cited by in Crossref: 59] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
48 Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2006;18:689-692. [PMID: 16702861 DOI: 10.1097/00042737-200606000-00018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
49 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
50 Summers KL, Marleau AM, Mahon JL, McManus R, Hramiak I, Singh B. Reduced IFN-alpha secretion by blood dendritic cells in human diabetes. Clin Immunol. 2006;121:81-89. [PMID: 16859998 DOI: 10.1016/j.clim.2006.05.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
51 Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423-431. [PMID: 16341948 DOI: 10.1007/s11096-005-1319-7] [Cited by in Crossref: 129] [Cited by in F6Publishing: 116] [Article Influence: 8.1] [Reference Citation Analysis]
52 Stepniak D, Koning F. Celiac disease--sandwiched between innate and adaptive immunity. Hum Immunol. 2006;67:460-468. [PMID: 16728270 DOI: 10.1016/j.humimm.2006.03.011] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
53 Ebert EC. Gastrointestinal complications of diabetes mellitus. Dis Mon. 2005;51:620-663. [PMID: 16458726 DOI: 10.1016/j.disamonth.2005.11.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
54 Coco G, Dal Pra C, Presotto F, Albergoni MP, Canova C, Pedini B, Zanchetta R, Chen S, Furmaniak J, Rees Smith B, Mantero F, Betterle C. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 2006;91:1637-45. [PMID: 16522688 DOI: 10.1210/jc.2005-0860] [Cited by in Crossref: 83] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
55 Alazemi S, Campos MA. Interferon-induced sarcoidosis: INTERFERON-INDUCED SARCOIDOSIS. International Journal of Clinical Practice 2006;60:201-11. [DOI: 10.1111/j.1742-1241.2005.00651.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
56 Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, Wintermeyer P, Jenke A. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-8. [PMID: 15793840 DOI: 10.1002/hep.20661] [Cited by in Crossref: 147] [Cited by in F6Publishing: 107] [Article Influence: 8.6] [Reference Citation Analysis]
57 Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005;204:9-26. [DOI: 10.1111/j.0105-2896.2005.00252.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 126] [Article Influence: 7.9] [Reference Citation Analysis]
58 Betterle C, Coco G, Zanchetta R. Adrenal cortex autoantibodies in subjects with normal adrenal function. Best Practice & Research Clinical Endocrinology & Metabolism 2005;19:85-99. [DOI: 10.1016/j.beem.2004.11.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
59 LaRochelle JS, Karp BI. Restless legs syndrome due to interferon-alpha. Mov Disord. 2004;19:730-731. [PMID: 15197722 DOI: 10.1002/mds.20049] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
60 Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep. 2004;4:194-198. [PMID: 15132884 DOI: 10.1007/s11892-004-0023-7] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
61 Devendra D, Eisenbarth GS. Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol. 2004;111:225-233. [PMID: 15183143 DOI: 10.1016/j.clim.2004.01.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 3.9] [Reference Citation Analysis]
62 Brok J, Mellerup MT, Krogsgaard K, Gluud C; Cochrane Hepato-Biliary Group. Glucocorticosteroids for viral hepatitis C. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd002904.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
63 Primo Vera J. Diabetes mellitus tipo 1 inducida por interferón pegilado en 2 pacientes con hepatitis crónica c. Gastroenterología y Hepatología 2004;27:69. [DOI: 10.1016/s0210-5705(03)79089-x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]